查詢結果分析
相關文獻
- Neoadjuvant Trastuzumab Concurrent with Nonanthracycline-based Regimens for HER2-positive Locally Advanced Breast Cancer
- 賀癌平(Herceptin)/化學治療在轉移性乳癌之角色
- Treatment Outcome in Women with Operable HER2-positive Breast Cancer: A Single Institutional Report
- Cardiotoxicity Associated with Trastuzumab Therapy in Taiwan: A Single Medical Center's 5-Year Experience
- Fever, Rash and Acute Inflammatory Polyarthritis in a Breast Cancer Patient after Trastuzumab Treatment: a Case Report
- HER2陽性轉移性乳癌之標靶藥物回顧
- Trastuzumab for HER-2-Positive Advanced Salivary Gland Cancer
- Durable Response to Lapatinib Plus Capecitabine in Trastuzumab--Resistant HER2 Over-expressing Metastatic Breast Cancer
- 細胞表皮生長因子受體與乳癌標靶治療
- A Case Discussion of Locally Advanced Breast Cancer Enrolled in the ALTTO Trial
頁籤選單縮合
題 名 | Neoadjuvant Trastuzumab Concurrent with Nonanthracycline-based Regimens for HER2-positive Locally Advanced Breast Cancer=賀癌平針對局部晚期乳癌的前導性治療 |
---|---|
作 者 | 劉韋新; 劉美瑾; 余本隆; 鄭鴻鈞; 李明媛; 鍾奇峰; 王宗德; 洪啟峰; | 書刊名 | 臺灣癌症醫學雜誌 |
卷 期 | 1:2 2014.09[民103.09] |
頁 次 | 頁163-171 |
分類號 | 418.31 |
關鍵詞 | 賀癌平; 局部晚期乳癌; 前導性治療; 病理性完全反應; Trastuzumab; Locally advanced breast cancer; Neoadjuvant therapy; Pathologic complete response; pCR; |
語 文 | 英文(English) |
中文摘要 | 賀癌平(Trastuzumab)是一種作用於人類表皮生長因子受體 II (HER-2)的單株抗體。目 前賀癌平已證實對於 HER-2 過度表現的乳癌有臨床上的效益。針對初期乳癌(第一期至第三期)術後的輔助性治療,賀癌平搭配化學治療為目前治療的準則。然而,針對局部晚期 乳癌術前所給予的前導性治療,賀癌平所扮演的角色目前仍不確定。但有越來越多的文 獻指出,賀癌平合併化學治療作為局部晚期乳癌的前導性治療有臨床上的助益。我們於 此做一個個案報告,病患是一位 47 歲女性,診斷為 HER-2 陽性的局部晚期乳癌。病患接 受化學治療合併賀癌平作為前導性治療,術後達病理性完全反應,且目前超過 5 年無疾 病復發證據。最後,我們對於賀癌平在前導性治療所扮演的角色做了文獻回顧。 |
英文摘要 | Trastuzumab, a humanized monoclonal antibody directed against the external domain of the HER-2 protein, has shown remarkable activity against HER-2 positive breast cancer. Consequently, the use of adjuvant trastuzumab plus chemotherapy in patients with HER2-positive stage breast cancer (stage I to III) has become the standard treatment option. However, the role of trastuzumab in neoadjuvant treatment therapy is still uncertain. An increasing number of clinical trials and inadequate analysis show the benefit of adding trastuzumab to chemotherapy in the neoadjuvant setting. We report a case of HER2-positive locally advanced breast cancer in a patient who received cytotoxic agents concomitant with trastuzumab as neoadjuvant therapy, and also review the published literature. The patient achieved pathological complete response, and remained disease-free for more than 5 years. |
本系統中英文摘要資訊取自各篇刊載內容。